文献速递神经MR

基于Transformer的MRI模型预测胶质母细胞瘤替莫唑胺耐药

A Transformer-Based Deep Learning Model for Prediction of Temozolomide Resistance in Glioblastoma Using Pretreatment MRI Images.
PubMed 文献 · Acad Radiol · 2026-09-10

本研究回顾性纳入4个中心314例胶质母细胞瘤患者,基于治疗前MRI图像开发Vision Transformer深度学习模型,联合MGMT甲基化状态构建融合模型预测替莫唑胺耐药。融合模型在训练、内部验证及两个外部验证队列中均优于单一模型,AUC分别为0.855、0.917、0.806和0.848,决策曲线分析显示较高净临床获益。

要点

  • 融合模型联合MRI深度学习特征与MGMT甲基化状态,可术前预测替莫唑胺耐药风险。
  • 瘤周10 mm为最佳扩展距离,构建深度学习模型时应注意包含瘤周浸润区域。
  • 预测耐药者可避免无效化疗,预测敏感者可考虑更积极的治疗策略。

核心结论

  • 融合模型预测胶质母细胞瘤替莫唑胺耐药的AUC在训练、内部验证及两个外部验证队列中分别为0.855(95% CI,0.802-0.905)、0.917(95% CI,0.737-1.000)、0.806(95% CI,0.632-0.937)和0.848(95% CI,0.673-0.964)。
  • 决策曲线分析显示融合模型可提供较高的净临床获益。
  • 该融合模型可为胶质母细胞瘤患者提供精准的替莫唑胺耐药个体化风险评估。

研究设计与样本

  • 队列划分为训练队列、内部验证队列和两个外部验证队列。
  • 耐药与敏感分组依据为Stupp同步放化疗后的最佳影像学反应。
  • 采用Vision Transformer架构开发深度学习网络,通过选择最佳瘤周扩展距离构建模型。

关键影像表现/征象

  • 深度学习模型的构建选择了瘤周10 mm扩展距离作为最佳参数。

诊断标准与关键数值

  • 融合模型在训练队列中预测替莫唑胺耐药的AUC为0.855(95% CI,0.802-0.905)。
  • 融合模型在内部验证队列中预测替莫唑胺耐药的AUC为0.917(95% CI,0.737-1.000)。
  • 融合模型在两个外部验证队列中预测替莫唑胺耐药的AUC分别为0.806(95% CI,0.632-0.937)和0.848(95% CI,0.673-0.964)。
  • 融合模型在训练、内部验证及外部验证队列中均优于单独的深度学习网络模型和MGMT甲基化状态。
  • 替莫唑胺耐药与敏感分组的标准为Stupp同步放化疗后的最佳影像学反应。

临床应用与阅片要点

  • 临床阅片时胶质母细胞瘤瘤周10 mm区域的信息对预测替莫唑胺耐药具有重要价值,报告可关注该范围的异常信号。
  • 结合治疗前MRI预测模型与MGMT甲基化状态,可帮助筛选可能从替莫唑胺化疗中获益的患者。
  • 对于预测耐药的患者可避免不必要的化疗,对于预测敏感的高危患者可考虑更积极的治疗策略。

局限性

  • 回顾性研究设计,存在选择偏倚的可能。
  • 虽然包含4个中心,但未说明各中心样本量分布及中心间异质性控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Glioblastoma (GBM) is a lethal tumor where temozolomide (TMZ) chemotherapy often faces resistance. We develop a deep learning model based on a Vision Transformer (ViT) architecture for pretreatment prediction of TMZ resistance.

METHODS: We retrospectively enrolled 314 GBM patients across four centers between January 2021 and December 2024. The cohort was divided into a training cohort, an internal validation cohort, and two external validation cohorts. Patients were categorized into resistant and sensitive groups based on the best radiological response after Stupp chemoradiotherapy. A ViT-based deep learning network (DLN) was developed by selecting the optimal peritumoral expansion margin. A fusion model was subsequently constructed by concatenating the DLN with MGMT methylation status. Model performance was evaluated using calibration and decision curve analysis (DCA).

RESULTS: An expansion distance of 10 mm was selected as optimal for constructing the DLN model. The fusion model outperformed both the DLN and the MGMT in the training, internal validation, and external validation cohorts, demonstrating robust performance in predicting TMZ resistance with Area Under the Curve (AUC) values of 0.855 (95% CI, 0.802-0.905), 0.917 (95% CI, 0.737-1.000), 0.806 (95% CI, 0.632-0.937), and 0.848 (95% CI, 0.673-0.964), respectively. Decision curve analysis indicated that the fusion model provided a high net clinical benefit.

CONCLUSION: The fusion model provides a precise and personalized risk assessment for TMZ resistance in GBM. This approach has the potential to spare resistant patients from unnecessary chemotherapy while identifying high-risk individuals who may benefit from more aggressive treatment strategies.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Xue, Li, Li, et al. A Transformer-Based Deep Learning Model for Prediction of Temozolomide Resistance in Glioblastoma Using Pretreatment MRI Images. Acad Radiol. 2026. PMID: 42722555. doi:10.1016/j.acra.2026.08.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。